Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9542887 | 0.83 | HPGD (0.50) | RAB9AKMT2AMEN1ALDH1A1TP53 | |
| SCHEMBL1489033 | 0.81 | RAB9A (0.47) | RAB9AKMT2AMEN1KDM4ELMNA | |
| SCHEMBL696965 | 0.81 | RAB9A (0.47) | RAB9AKMT2AMEN1KDM4ELMNA | |
| SCHEMBL306765 | 0.81 | ALDH1A1 (0.63) | RAB9AKMT2AMEN1KDM4ELMNA | |
| SCHEMBL1786128 | 0.79 | LMNA (0.50) | RAB9AKMT2AMEN1KDM4ELMNA | |
| SCHEMBL9586276 | 0.78 | ALDH1A1 (0.65) | RAB9AKDM4ELMNAALDH1A1TP53 | |
| Hydrochloric Acid SCHEMBL28752341 | 0.78 | LMNA (0.49) | RAB9AKMT2AMEN1KDM4ELMNA | |
| SCHEMBL3187679 | 0.77 | CSNK2A1 (0.67) | RAB9AKMT2AMEN1KDM4ELMNA | |
| SCHEMBL9524539 | 0.77 | CSNK2A1 (0.45) | KMT2AMEN1LMNACSNK2A1ALDH1A1 | |
| SCHEMBL844384 | 0.76 | MEN1 (0.54) | RAB9AKMT2AMEN1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379525-B1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMA INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1679313-A2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | BERGMANIS ARIJA A | 2005-11-17 | — | — | US | disclosed |
| EP-1210344-B1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMA INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-6956052-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| EP-1582519-A2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1210344-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6303659-B2 | Compounds | ASTRAZENECA AB (SE) | 2001-10-16 | — | — | US | disclosed |
| US-6258838-B1 | Compounds | ASTRAZENECA AB (SE) | 2001-07-10 | — | — | US | disclosed |
| US-20010003121-A1 | Novel compounds | ASTRAZENECA UK LIMITED | 2001-06-07 | — | — | US | disclosed |
| US-6201024-B1 | EFFECTIVE P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISORDERS | ASTRAZENECA UK LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| WO-2001012627-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| EP-1036059-A1 | ADAMANTANE DERIVATIVES | AstraZeneca UK Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999029661-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
| CN-1033031-C | Modified gangliosides and functional derivatives thereof | FIDIA SPA (IT) | 1996-10-16 | — | — | CN | disclosed |
| CN-1051912-A | Improved gangliosides and functional derivatives thereof | FIDIA B P A (IT) | 1991-06-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | RAB9A 1813/4885KMT2A 2012/4885MEN1 3960/4885 |
| US-20060189661-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | RAB9A 1813/4885KMT2A 2012/4885MEN1 3960/4885 |
| US-20010003121-A1 | Novel compounds | APP, BACE1, CHRNA5 | RAB9A 486/4885KMT2A 4437/4885MEN1 1930/4885 |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | RAB9A 3170/4885KMT2A 3225/4885MEN1 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.